Intellia Therapeutics is trading 7.48% up now at $13.63 after closing at $12.69 on September 1, 2026, with no confirmed company-specific catalyst identified.

  • No confirmed September 1 announcement, earnings release, regulatory decision, or transaction was identified.
  • Intellia Therapeutics is scheduled to participate in the Bradykinin Symposium on September 2-3, but reporting does not directly link it to the move.
  • Broader markets declined, so global sentiment does not clearly explain the contrary move.